Literature DB >> 22733074

Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum.

Keith Cássia da Cunha1, Deanna A Sutton, Josepa Gené, Javier Capilla, Josep Cano, Josep Guarro.   

Abstract

Exserohilum is an agent of human and animal mycoses. Although classification has been based on a few subtle morphological differences, three species of clinical interest have been traditionally accepted. In this study, by using a multigene sequence analysis, we have demonstrated that Exserohilum longirostratum and E. mcginnisii are probable synonyms of E. rostratum. The isolates tested were mainly from the nasal region. Antifungal susceptibility testing demonstrated high activity of the eight agents tested against this fungus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733074      PMCID: PMC3421891          DOI: 10.1128/AAC.00488-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Reliable amplification of actin genes facilitates deep-level phylogeny.

Authors:  K Voigt; J Wöstemeyer
Journal:  Microbiol Res       Date:  2000-09       Impact factor: 5.415

2.  Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens.

Authors:  Anna Lau; Sharon Chen; Tania Sorrell; Dee Carter; Richard Malik; Patricia Martin; Catriona Halliday
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

3.  Keratomycosis due to Exserohilum rostratum - a case report.

Authors:  B V Peerapur; S D Rao; S Patil; B G Mantur
Journal:  Indian J Med Microbiol       Date:  2004 Apr-Jun       Impact factor: 0.985

4.  In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi.

Authors:  M R McGinnis; L Pasarell
Journal:  Med Mycol       Date:  1998-08       Impact factor: 4.076

5.  An evaluation of the in vitro activity of terbinafine.

Authors:  C J Jessup; N S Ryder; M A Ghannoum
Journal:  Med Mycol       Date:  2000-04       Impact factor: 4.076

6.  Phaeohyphomycosis of the nasal sinuses caused by a new species of Exserohilum.

Authors:  A A Padhye; L Ajello; M A Wieden; K K Steinbronn
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

7.  Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum.

Authors:  M R McGinnis; M G Rinaldi; R E Winn
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

8.  Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.

Authors:  José Luis Arredondo-García; Carlos F Amábile-Cuevas
Journal:  J Infect Dev Ctries       Date:  2009-06-01       Impact factor: 0.968

9.  Hospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia.

Authors:  Maude Saint-Jean; Guy St-Germain; Céline Laferrière; Bruce Tapiero
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-05       Impact factor: 2.471

Review 10.  A case of cutaneous phaeohyphomycosis caused by Exserohilum rostratum, its in vitro sensitivity and review of literature.

Authors:  A Agarwal; S M Singh
Journal:  Mycopathologia       Date:  1995-07       Impact factor: 2.574

View more
  20 in total

1.  In Vitro Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates.

Authors:  Anuradha Chowdhary; Ferry Hagen; Ilse Curfs-Breuker; Hugo Madrid; G Sybren de Hoog; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

2.  Fungal disease following contaminated steroid injections: Exserohilum is ready for its close-up.

Authors:  Marta Feldmesser
Journal:  Am J Pathol       Date:  2013-07-19       Impact factor: 4.307

3.  CNS Mold Infections.

Authors:  Jennifer L Lyons
Journal:  Curr Infect Dis Rep       Date:  2013-10-13       Impact factor: 3.725

4.  Whole-genome analysis of Exserohilum rostratum from an outbreak of fungal meningitis and other infections.

Authors:  Anastasia P Litvintseva; Steven Hurst; Lalitha Gade; Michael A Frace; Remy Hilsabeck; James M Schupp; John D Gillece; Chandler Roe; David Smith; Paul Keim; Shawn R Lockhart; Shankar Changayil; M Ryan Weil; Duncan R MacCannell; Mary E Brandt; David M Engelthaler
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

5.  A real-time PCR assay for rapid detection and quantification of Exserohilum rostratum, a causative pathogen of fungal meningitis associated with injection of contaminated methylprednisolone.

Authors:  Yanan Zhao; Ruta Petraitiene; Thomas J Walsh; David S Perlin
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

6.  Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States.

Authors:  Peter G Pappas; Dimitrios P Kontoyiannis; John R Perfect; Tom M Chiller
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

7.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

8.  What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?

Authors:  Dimitrios P Kontoyiannis; David S Perlin; Emmanuel Roilides; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-05-06       Impact factor: 9.079

9.  In vitro studies of Exserohilum rostratum with antifungal drugs and methylprednisolone.

Authors:  S G Revankar; V Moudgal; P Chandrasekar; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

10.  Detection of fungal DNA in human body fluids and tissues during a multistate outbreak of fungal meningitis and other infections.

Authors:  Lalitha Gade; Christina M Scheel; Cau D Pham; Mark D Lindsley; Naureen Iqbal; Angela Ahlquist Cleveland; Anne M Whitney; Shawn R Lockhart; Mary E Brandt; Anastasia P Litvintseva
Journal:  Eukaryot Cell       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.